NCT04960124

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

An Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of JNJ-42847922 in Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-42847922 in adult participants with hepatic impairment when compared to healthy participants with normal hepatic function.

Conditions

• Healthy
• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	JNJ-42847922	Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Timeline

• Start date: 2021-08-05
• Primary completion: 2021-11-19
• Completion: 2021-11-19
• First posted: 2021-07-13
• Last updated: 2025-04-27

Locations

2 sites across 1 country: Germany

Regulatory

• FDA-regulated drug study